Austin, TX 12/10/2007 11:21:18 PM
Speak with other shareholders about: (Nasdaq: IMGN), (Nasdaq: TELK), (Nasdaq: MLNM), (Nasdaq: EPCT)
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the Chat Live button at the top.
----------------------------------------------------------
Chat real-time with other investors about this IMGN news release,
by clicking this link: http://www.stockwire.com/IMGN
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=IMGN
ImmunoGen (Nasdaq: IMGN) Closed at $4.79. Today announced that encouraging clinical findings with the TAP compound, AVE9633, were reported today at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition. AVE9633 demonstrated evidence of biological activity in multiple patients with relapsed/refractory acute myeloid leukemia (AML) and was found to be generally well tolerated.
Highly favorable preclinical findings also were reported for SAR3419, a TAP compound now in clinical testing for the treatment of non-Hodgkin's lymphoma and other B-cell malignancies.
----------------------------------------------------------
Chat real-time with other investors about this TELK news release,
by clicking this link: http://www.stockwire.com/TELK
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=TELK
Telik (Nasdaq: TELK) Closed at $3.60. Today announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The data were reported at the 49th annual meeting of the American Society of Hematology in Atlanta.
The objectives of the trial were to evaluate the safety and pharmacokinetics of TELINTRA Tablets (also known as TLK199 Tablets), and obtain preliminary indications of efficacy (International Working Group, IWG, 2000 criteria). The trial enrolled 45 patients and included all WHO classifications of MDS. Patients received one of ten dose levels of TELINTRA Tablets taken daily for seven days followed by two weeks of follow-up. Patients could receive planned therapy up to six months (eight cycles) until MDS progression or unacceptable toxicity.
----------------------------------------------------------
Chat real-time with other investors about this MLNM news release,
by clicking this link: http://www.stockwire.com/MLNM
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=MLNM
Millennium Pharmaceuticals (Nasdaq: MLNM) Closed at $15.07. Today announced the presentation of results from an interim analysis of the first 256 patients evaluated in a multi-center, randomized Phase III clinical trial. This study compared VELCADE, thalidomide and dexamethasone (VcTD) to thalidomide and dexamethasone (TD) alone, currently the most commonly used U.S. regimen for patients with previously untreated multiple myeloma (MM). The trial was conducted by the Italian Myeloma Network (GIMEMA) cooperative group and selected for an oral presentation at the American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Ga., December 8- 11, 2007.
"This VELCADE based induction regimen achieved a fourfold increase in the complete remission rate. Complete remission is widely recognized as a predictor for long-term survival," said Professor Michele Cavo, M.D., Seragnoli Institute of Hematology, University of Bologna and Principal Investigator of the trial. "These exciting results demonstrated that adding VELCADE to the standard induction therapy prior to stem cell transplantation improves the response rate dramatically."
----------------------------------------------------------
Chat real-time with other investors about this EPCT news release,
by clicking this link: http://www.stockwire.com/EPTCT
To view in-depth research, click the following
link: http://www.stockwire.com/detailed/analysis.php?company=EPCT
EpiCept Corporation (Nasdaq: EPCT) Closed at $1.44. Today announced new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years among Acute Myeloid Leukemia (AML) patients who receive post-consolidation immunotherapy with Ceplene(TM) (histamine dihydrochloride) in conjunction with low dose interleukin-2 (IL-2). These data were presented on December 9th at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta.
"This ASH meeting shows the tremendous progress ImmunoGen has made in recent years," commented Mitchel Sayare, Chairman and CEO. "In the past two days, impressive clinical findings were reported with two TAP compounds - IMGN901 and AVE9633 - in the treatment of multiple myeloma and acute myeloid leukemia, respectively, and highly favorable preclinical data were reported with a third TAP compound, SAR3419, for the treatment of lymphomas. In addition to the AVE9633 and SAR3419 findings presented, our collaborator sanofi-aventis also reported very encouraging clinical data on the naked antibody, AVE1642, that we initially developed and now is in broad development by them."
--------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the National Association of Securities Dealers (NASDAQ) at www.NASDAQ.com. The NASDAQ has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We often receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares into the open market.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
